A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid
| 대상 질환 | Asthma |
|---|---|
| 임상 단계 | 3상 |
| 스폰서 | Chiesi Farmaceutici S.p.A. |
| 상태 | 완료 |
| 참여자 수 | 1,377 명 |
| 중재(약물) | Beclomethasone Dipropionate/Formoterol Fumarate, Beclomethasone Dipropionate |
| 시작일 | 2022년 8월 31일 |
| 완료일 | 2024년 6월 24일 |
| 결과 공개일 | 2025년 9월 4일 |
요약
Compare the superiority of CHF 1535 versus CHF 718 in subjects with asthma who are on medium or high dose inhaled corticosteroids.
1_Change From Baseline in FEV1 AUC0-12h Normalised by Time at Week 12
| CHF 1535 pMDI | 0.279 liter |
|---|---|
| CHF 718 pMDI | 0.174 liter |
| p-value | <0.001 |
|---|---|
| Adjusted mean difference | 0.104 (95% CI 0.061–0.148) |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- A Study of Remote Asthma Management Using an Integrated Artificial Intelligence-assisted E — Mayo Clinic
- Developing a Childhood Asthma Risk Passive Digital Marker — Indiana University
- A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to — Hoffmann-La Roche
- A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Cortic — Hoffmann-La Roche
- Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Sev — AstraZeneca
- Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma — ARS Pharmaceuticals, Inc.